Moderna Inc. is seeing its share prices jump up 16% as of the premarket trade following their announcement that their Coronavirus vaccine candidate, mRNA-1273 showed an effectiveness rate of 94.5% during its Phase 3 trials. This announcement comes following last Monday’s announcement from Pfizer on their 90% effective Coronavirus vaccine. The announcement from Pfizer subsequently caused theater shares to rise and stay-at-home businesses to drop.
Moderna Inc. revealed in a press release that they seek to file for an Emergency Use Authorization with the FDA within a few weeks. This is overlooking the fact that no outside source or peer-reviewed journal has supported Moderna’s findings as of yet. The company has also made the statement that their vaccine maintains stability inside standard refrigeration temperatures for 30 days. Its also been reported that their vaccine maintains its effectiveness for 12 hours at room temperature. It also won’t require any special kind of handling leading us to believe that it may be distributed in standard clinics & pharmacies.
Stay in the know with the latest culture news